[Current aspects on the treatment of endometriosis].
The aim of pharmacological treatment of endometriosis is to reduce estrogen levels, which may be achieved using gestagens or GnRH-agonists. The effects of the different hormones are mainly the same, while side effects differ. If the GnRH-agonist dose is modified, or if a low dose of estrogen and/or gestagen is given in addition, the hypo-estrogenic side effects of GnRH-agonists can be reduced. Surgical treatment can often be performed in conjunction with diagnostic laparoscopy. Supplementary hormonal treatment may postpone recurrence. Because endometriosis is in many women a chronically recurring disorder, continuity in the doctor-patient relationship is essential.
Bergqvist
A
A
Kvinnokliniken, Huddinge sjukhus.
Bergquist
C
C
Nordenskjöld
F
F
D000700:Analgesics / Q000008:administration & dosage; D003266:Continuity of Patient Care; D003613:Danazol / Q000008:administration & dosage; D004715:Endometriosis / Q000188:drug therapy / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D004965:Estrogen Antagonists / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000009:adverse effects; D006728:Hormones / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D010535:Laparoscopy; D017274:Nafarelin / Q000008:administration & dosage / Q000009:adverse effects; D011372:Progestins / Q000008:administration & dosage / Q000009:adverse effects; D012008:Recurrence
D000700:Analgesics; D004965:Estrogen Antagonists; D006728:Hormones; D011372:Progestins; D017274:Nafarelin; D007987:Gonadotropin-Releasing Hormone; D003613:Danazol